Updated results of a phase II study of gemcitabine, erlotinib, and S-1 in patients with advanced pancreatic cancer.

被引：1
|
作者：
Han, Boram
Kim, Hyeong Su
Choi, Dae Ro
Shim, Byoung Yong
Lee, Kyung Hee
Kim, Jin Won
Kim, Jung Han
Kim, Jung Hoon
Kim, Ho Young
Song, Hunho
Park, Choong Kee
Moon, Sung Hoon
Kim, Jong Hyeok
Jeon, Jang Yong
Lee, Jung Woo
Zang, Dae Young
机构：
[1] Hallym Univ, Med Ctr, Anyang, South Korea
[2] Hallym Univ, Med Ctr, Coll Med, Seoul, South Korea
[3] Hallym Univ, Chuncheon Sacred Heart Hosp, Chunchon, South Korea
[4] Cathol Univ Kore, St Vincents Hosp, Seoul, South Korea
[5] Yeungnam Univ Hosp, Dept Hemato Oncol, Daegu, South Korea
[6] Seoul Natl Univ Bundang Hosp, Dept Internal Med, Seoul, South Korea
[7] Hallym Univ, Coll Med, Med Ctr, Dept Internal Med, Anyang, South Korea
[8] Hallym Univ, Chuncheon Sacred Heart Hosp, Div Hematol Oncol, Dept Internal Med, Chunchon, South Korea
[9] Hallym Univ, Kang Dong Sacred Heart Hosp, Med Ctr, Seoul, South Korea
[10] Hallym Univ, Med Ctr, Anyang, South Korea
[11] Hallym Univ, Sacred Heart Hosp, Dept Internal Med, Anyang, South Korea
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2017年 / 35卷
关键词：
D O I：
10.1200/JCO.2017.35.15_suppl.e15778
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e15778
引用
下载
收藏
页数：6
相关论文
共 50 条
  • [41] S-1 IN COMBINATION WITH GEMCITABINE FOR ADVANCED PANCREATIC CANCER
    Sudo, K.
    Yamaguchi, T.
    Nakamura, K.
    Hara, T.
    Ishihara, T.
    Denda, T.
    ANNALS OF ONCOLOGY, 2008, 19 : 185 - 185
  • [42] Phase Ib study of gemcitabine and oxaliplatin with erlotinib in patients with advanced biliary tract cancer.
    Ciombor, Kristen Keon
    Cardin, Dana Backlund
    Chan, Emily
    McClanahan, Pamela
    Fan, Kang-Hsien
    Flynn, Jayme
    Young, Ruth T.
    DeMers, April
    Smith, Stephen James
    Berlin, Jordan
    Goff, Laura Williams
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [43] A randomized phase II clinical trial of gemcitabine, oxaliplatin, erlotinib combination chemotherapy versus gemcitabine and erlotinib in previously untreated patients with locally advanced or metastatic pancreatic cancer.
    Lim, Sung Hee
    Yun, Jina
    Lee, Min-Young
    Kim, Han Jo
    Kim, Kyoung Ha
    Kim, Se Hyung
    Lee, Sang-Cheol
    Bae, Sang Byung
    Kim, Chan Kyu
    Lee, Namsu
    Lee, Kyu Taek
    Park, Sung Kyu
    Hong, Dae Sik
    Choi, Hyun Jong
    Moon, Jong Ho
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (04)
  • [44] A phase I study of combination chemotherapy with gemcitabine and oral S-1 for advanced pancreatic cancer
    Ueno, H
    Okusaka, T
    Ikeda, M
    Ishiguro, Y
    Morizane, C
    Matsubara, J
    Furuse, J
    Ishii, H
    Nagase, M
    Nakachi, K
    ONCOLOGY, 2005, 69 (05) : 421 - 427
  • [45] A phase II study of induction chemotherapy with gemcitabine plus S-1 followed by chemoradiotherapy for locally advanced pancreatic cancer
    Kohei Nakachi
    Junji Furuse
    Taira Kinoshita
    Mitsuhiko Kawashima
    Hiroshi Ishii
    Masafumi Ikeda
    Shuichi Mitsunaga
    Satoshi Shimizu
    Cancer Chemotherapy and Pharmacology, 2010, 66 : 527 - 534
  • [46] A phase II study of induction chemotherapy with gemcitabine plus S-1 followed by chemoradiotherapy for locally advanced pancreatic cancer
    Nakachi, Kohei
    Furuse, Junji
    Kinoshita, Taira
    Kawashima, Mitsuhiko
    Ishii, Hiroshi
    Ikeda, Masafumi
    Mitsunaga, Shuichi
    Shimizu, Satoshi
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2010, 66 (03) : 527 - 534
  • [47] A phase II study of erlotinib in patients (pts) with advanced pancreatic cancer (APC) who are refractory to gemcitabine (G)
    Iyer, R.
    Khushalani, N.
    Tan, W.
    Litwin, A.
    LeVea, C.
    Hutson, A.
    Tucker, C.
    Ma, W.
    Fakih, M.
    Adjei, A.
    EJC SUPPLEMENTS, 2009, 7 (02): : 391 - 391
  • [48] A phase II study of S-1 in patients with metastatic pancreatic cancer
    Funakoshi, A.
    Okusaka, T.
    Furuse, J.
    Boku, N.
    Yamao, K.
    Ohkawa, S.
    Saito, H.
    EJC SUPPLEMENTS, 2005, 3 (02): : 220 - 220
  • [49] A phase II randomized, placebo controlled study to evaluate the efficacy of the combination of gemcitabine, erlotinib, and metformin in patients with locally advanced or metastatic pancreatic cancer.
    Wilmink, Johanna
    Kordes, Sil
    Zwinderman, Koos
    Mathot, Ron
    Punt, Cornelis J. A.
    Richel, Dirk
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [50] A phase II trial of Erlotinib in combination with gemcitabine and cisplatin in advanced pancreatic cancer
    Hwang, In Gyu
    Jang, Joung-Soon
    Oh, Sung Yong
    Lee, Suee
    Kwon, Hyuk Chan
    Lee, Gyeong Won
    Go, Seil
    Kang, Myoung Hee
    Cha, Young Joo
    Kang, Jung Hun
    INVESTIGATIONAL NEW DRUGS, 2012, 30 (06) : 2371 - 2376
12345